Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 19/20 | 0.85 |
| ▸ | SRD5A2 | P31213 | 8/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.85 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.85 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000656 | 1.00 | SRD5A1 (0.85) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1559596 | 0.92 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL20776136 | 0.92 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1108295 | 0.92 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL5903 | 0.92 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL10028296 | 0.92 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL4775587 | 0.92 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1832772 | 0.92 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL9975973 | 0.92 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL12194984 | 0.92 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911508-B2 | Microparticles containing dutasteride, and preparation method therefor | INVENTAGE LAB INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20160287524-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT | GALENICUM HEALTH S.L. (ES) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287524-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT | NR5A1, HSD17B11, UGT2B17 | SRD5A1 20/4885SRD5A2 21/4885LMNA 1114/4885 |
| US-11911508-B2 | Microparticles containing dutasteride, and preparation method therefor | AR, BPHL, SHBG | SRD5A1 14/4885SRD5A2 22/4885LMNA 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.